Strong Sales Growth and Record Free Cash Flow
Alcon reported third quarter sales of $2.4 billion, representing a 6% growth. Core diluted earnings grew 25% to $0.81 per share, and the company generated a record $1.3 billion in free cash flow for the first nine months of the year.
Innovative Product Launches
Alcon announced the launch of Precision7, a new 1-week replacement contact lens, and Systane Pro preservative-free, a new formulation for dry eyes. Additionally, the company completed the migration of all intraocular lenses to the Clareon material.
Strategic Arrangement with OcuMension Therapeutics
Alcon finalized a strategic arrangement with OcuMension Therapeutics in China, receiving approximately 17% equity in the company and royalties on existing business.
Positive Market Dynamics
Global procedures in cataracts grew approximately 4%, and global AT-IOL penetration was up approximately 200 basis points year-over-year.